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The looming threat of a new influenza virus pandemic has fueled ambitious efforts to devise more
predictive parameters for assessing the risks associated with emergent virus strains. At the same
time, a comprehensive understanding of critical factors that can accurately predict the outcome of
vaccination is sorely needed in order to improve the effectiveness of influenza virus vaccines. Will
new studies aimed at identifying adaptations required for virus transmissibility and systems-level
analyses of influenza virus vaccine responses provide an improved framework for predictive
models of viral adaptation and vaccine efficacy?Introduction
The development of effective vaccines
has altered the course of modern civiliza-
tion by alleviating the scourges of
humankind’s most devastating patho-
gens. Illnesses caused by variola (small-
pox), Corynebacterium diphtheriae (diph-
theria), Clostridium tetani (tetanus),
yellow fever virus (yellow fever), Borde-
tella pertussis (whooping cough), polio vi-
rus (polio), and measles virus (measles)
have become as foreign to our youngest
generations as telegrams and type-
writers. Indeed, the success of vaccines
to date is truly remarkable when con-
sidered in light of the rudimentary
principles that guided their historical
design (Stern and Markel, 2005). Ironi-
cally though, triumphs in the modern
era of ‘‘rationale vaccine design’’ have
been few and far between. Pathogens
such as Mycobacterium tuberculosis
(tuberculosis), Plasmodium spp. (causa-
tive agents of malaria), human immuno-
deficiency virus (HIV), and influenza
A virus (IAV) continue to elude broad
and highly efficacious vaccine-mediated
protection, exerting devastating human
and economic tolls. The factors that
have limited the successful design of
vaccines against these pathogens are
complex. However, two prominent
barriers stand out: (1) highly mutable/
adaptable pathogens such as HIV and
IAV evolve under immunological pres-294 Cell 157, April 10, 2014 ª2014 Elsevier Insure to evade the pre-existing immunity
afforded by vaccines. This has necessi-
tated painstaking efforts to identify and
target conserved epitopes of these vi-
ruses (Julien et al., 2012). (2) There is
an astonishing paucity of robust, predic-
tive immunological markers of vaccine
efficacy. This, in turn, has precluded
a comprehensive, mechanistic under-
standing of what differentiates success-
ful vaccines from those that fail. The
recognition of these challenges has
ignited ambitious efforts to predict more
accurately the behavior of the aforemen-
tioned pathogens and the vaccines de-
signed to protect against them. Here,
we review recent advances within the
field of influenza virus research that are
attempting to provide a more predictive
basis for assessing the consequences
of viral adaptations and the efficacy of
vaccines, and we highlight the scientific
and regulatory boundaries that must be
overcome to achieve these goals. Two
new studies focused on these important
topics appear in this issue of Cell.
Linster, van Boheemen, and colleagues
(Linster et al., 2014) define a minimal
set of mutations (and their associated
phenotypes) that confer H5N1 viruses
with the propensity to transmit in ferrets,
and Tsang and colleagues (Tsang et al.,
2014) use a systems biology approach
to identify baseline immunological pre-
dictors of vaccine responses.c.‘‘Follow the Leader’’
The most challenging issue facing IAV
vaccinologists has always been the ne-
cessity to predict the antigenic character-
istics of vaccine strains months in
advance of the actual influenza season
in order to allow sufficient time for vaccine
production and distribution. This can be
equated to a game of virological ‘‘follow
the leader,’’ wherein the medical and
scientific communities are constantly
chasing the unpredictable evolutionary
trajectory of the virus. As a consequence
of this guesswork, antigenic mismatch
between strains included in the vaccine
and the strains that eventually circulate
is a regular occurrence. This can severely
limit the effectiveness of a given vaccine.
Of equal concern though is the sub-
optimal vaccine efficacy reported even
during seasons in which near-perfect
matches are achieved. Adding to this
complexity are the vastly different quali-
ties of responses elicited by the available
influenza vaccine formulations, most
notably those observed for inactivated,
split vaccines in comparison to live
attenuated vaccines (Osterholm et al.,
2012). Recognition of the limitations that
plague our current seasonal influenza
virus vaccine approaches has catalyzed
renewed efforts to understand and iden-
tify factors that may more accurately
predict vaccine responses. Nevertheless,
all of these issues pale in comparison to
Figure 1. Predictive Factors of Influenza Virus Transmission
A number of adaptations (shown in blue) in H5N1 IAV were observed to confer the ability to transmit from ferret to ferret. This gain of function in transmission was
accompanied by a loss of function in virulence. Predicting the pandemic risk associated with future outbreaks caused by novel IAV strains in humans will require
a comprehensive understanding of which strains are capable of zoonotic transmission, the adaptations required for sustained human-to-human transmission,
and the consequences of those adaptations on properties such as virulence and fitness. Siaa2,3Gal and Siaa2,6Gal = a 2,3-linked sialic acids and a 2,6-linked
sialic acids, respectively.the ever-present threat of a new and un-
expected IAV pandemic. This has led to
a redoubling of efforts to both detect
and assess the risks associated with iso-
lated epidemics caused by ‘‘exotic’’ IAV
strains.
Predicting Pandemics?
Emergence of the ‘‘swine-origin’’ H1N1
IAV strain in 2009 that swept through
Mexico and went on to cause the first
pandemic of the 21st century served as
a direct example of the inherent limita-
tions precluding the accurate prediction
of IAV dynamics (Girard et al., 2010).
Never before had an IAV pandemic been
caused by a virus carrying the same hem-
agglutinin (HA) and neuraminidase (NA)
subtypes as one of the circulating sea-
sonal strains. This served as an impetus
to not only bolster surveillance efforts,
but to also more thoroughly understand
viral molecular determinants of virulence
and transmission.
Despite the fact that at least 18 sub-
types of IAV hemagglutinin (HA, H) and
11 subtypes of neuraminidase (NA, N)
have so far been identified (Tong et al.,
2013), only IAVs carrying H1, H2, or H3
and N1 or N2 have proven capable of
sustaining transmission among humans
and of causing pandemics. However, iso-
lated outbreaks caused by other subtypes
of IAV occur sporadically, igniting fears
that a new pandemic may arise. Notable
modern examples of such outbreaks
have been those caused by H5N1 IAV in
(primarly) Southeast Asia and a recentflurry of human cases caused by H7N9
IAV in China. Both of these viruses are of
avian origin and are mainly transmitted
to humans through exposure to high titers
of virus from infected poultry (To et al.,
2013).
The recent threat of a potentially devas-
tating H5N1 pandemic prompted the NIH
to fund a series of proposals aimed at
identifying viral molecular determinants
thatmight indicate adaptations that would
confer the ability to transmit efficiently be-
tween mammals. This work, carried out
by the groups of Yoshiro Kawaoka at
The University of Wisconsin, Madison/
University of Tokyo, Japan and Ron
Fouchier at Erasmus University Rotter-
dam was first published in the journals
Nature and Science in May and June of
2012, respectively (Herfst et al., 2012;
Imai et al., 2012). The Kawaoka group
used an unbiased genetic approach to
generate a library of viruses containing
mutations in the globular head domain
of the HA from the A/Vietnam/1203/
2004 H5N1 isolate in a nonpathogenic,
mouse-adapted IAV background (PR8).
Despite having been derived from a virus
isolated from a human, this HA maintains
an avian-like preference for binding to
a2,3-linked sialic acids (Siaa2,3Gal),
whereas IAVs that circulate in humans
typically exhibit a preference for a2,6-
linked sialic acids (Siaa2,6Gal). The
authors identified a virus containing HA
mutations E119G/V152I/N224K/Q226L
that exhibited a receptor-binding profile
resembling that of a seasonal human IAVCellisolate. Further analysis demonstrated
that the N224K/Q226L mutations alone
were primarily responsible for the switch
from Siaa2,3Gal to Siaa2,6Gal binding
(Imai et al., 2012).
The H5 HA mutations that conferred
altered receptor binding characteristics
were then rescued in the pandemic
A/California/04/2009 (Cal/09) H1N1 virus
background to assess how a recombi-
nant of an avian H5N1 virus with the
circulating Cal/09 H1N1 virus might
behave. This strategy closely resembles
previous studies performed by the Perez
lab in the context of H9N2 IAV (Kimble
et al., 2011). Despite causing a switch
to human-like receptor binding, both
E119G/V152I/N224K/Q226L and N224K/
Q226L mutations tended to attenuate
virus replication in the respiratory tract
of ferrets. However, a secondary N158D
or N158K mutation (which abolishes
a glycosylation site at position 158)
that appeared in animals inoculated
with the N224K/Q226L variant improved
virus replication in the upper respiratory
tract. The combination of N158D/N224K/
Q226L mutations conferred the ability to
transmit between ferrets via respiratory
droplets. A fourth mutation, which
occurred naturally during the transmis-
sion experiment (T318I), enhanced the
stability of the HA molecule and further
enhanced transmission (Imai et al., 2012).
The Fouchier group used a similar but
more classical virological approach to
force adaptation of the A/Indonesia/5/
2005 strain of H5N1 for the mammalian157, April 10, 2014 ª2014 Elsevier Inc. 295
respiratory tract. Both wild-type A/
Indonesia/5/2005 and a ‘‘pre-adapted’’
recombinant virus containing a series
of introduced mutations (HA Q222L/
G224S is involved with switching receptor
binding preference from Siaa2,3Gal to
Siaa2,6Gal; PB2 E627K is related to a
temperature adaptation that facilitates
replication in the human upper respiratory
tract) were serially passaged ten times in
ferrets. Replication of the pre-adapted
virus improved with passaging, while
replication of the wild-type virus remained
unchanged. The only mutation common
among the wild-type and pre-adapted
viruses after passaging was HA T156A.
Strikingly, this mutation, like the N158D/
K mutation observed by the Kawaoka
group, abolished a putative N-linked
glycosylation site. The passage 10 virus
populations derived from animals inocu-
lated with the pre-adapted virus were
also capable of airborne transmission
between ferrets, whereas the wild-type
virus was not. All animals from which
transmitted virus was recovered main-
tained the mutations introduced during
pre-adaptation and also consistently
harbored two novel amino acid sub-
stitutions in HA, H103Y (located at the
trimer interface) and T156A (located
proximal to the receptor binding site).
However, the lowest number of sub-
stitutions relative to wild-type found in
an isolated transmissible virus was nine
(PB2-E627K, PB1-H99K, PB1-I368V,
HA-H103Y, HA-T156A, HA-Q222L, HA-
G224S, NP-R99K, and NP-S345N), which
led to uncertainty regarding the minimal
set of substitutions necessary to confer
transmissibility (Herfst et al., 2012).
In this issue of Cell, Linster, van Bohee-
men, et al. expand upon this earlier
work by elucidating the minimal set
of substitutions required for airborne
transmission of A/Indonesia/5/2005
H5N1 among ferrets and by describing
the phenotypes associated with each
change. In addition to the PB2-E627K,
HA-Q222L/G224S, andHA-T156A substi-
tutions described above, the authors
found that HA-H103Y (stabilized HA with
respect to high temperature and low pH)
and PB1-H99Y (increased polymerase
activity) constituted the minimal set of
mutations required to transmit virus
among ferrets (Linster et al., 2014). Criti-
cally, this type of analysis provides a296 Cell 157, April 10, 2014 ª2014 Elsevier Inmore complete picture of the phenotypic
properties of changes that may constitute
increased risk of H5N1 transmissibility
(Figure 1).
Taken together, these results sug-
gested that a re-assortant virus carrying
the HA of A/Vietnam/1203/2004 H5N1
and the remaining segments of A/
California/04/2009 H1N1 would require
as few as four amino acid substitutions
in the HA molecule to become transmis-
sible in mammals, whereas wild-type
A/Indonesia/5/2005 H5N1 might require
only five mutations (three in HA, one in
PB1, and one in PB2) (Herfst et al., 2012;
Imai et al., 2012). A meta-analysis of avail-
able H5N1 surveillance data revealed
that, although many of the substitutions
found to confer transmissibility among
ferrets are rare in nature, HA substitutions
N154D and T156A, which destroy an
N-linked glycosylation site, and the
PB2 E627K temperature adaptation are
much more common and regularly occur
together. Various mathematical models
were developed to predict the probability
that these substitutions would arise
together during a natural infection and
concluded that such a scenario was
indeed probable. However, the proportion
of viruses carrying the transmissible
genotype as a function of the total virus
population within a single host was
extremely low, which would likely present
a formidable barrier to efficient trans-
mission (Russell et al., 2012).
Though these studies have undoubt-
edly enhanced our understanding of
IAV transmissibility, their interpretability
is constrained by several scientific and
regulatory boundaries. Let us focus first
on some crucial scientific considerations.
The process of viral adaptation (particu-
larly via serial passaging in a new host)
has historically been exploited to achieve
attenuation of strains to be used for
vaccine formulation. This concept relies
on the biological principle that the adap-
tation of new traits (i.e., transmissibility)
is frequently accompanied by a loss
of other traits for which there is less
selective pressure (i.e., host range and/
or virulence). Indeed, the Fouchier
group observed that, although ferrets
succumbed to intranasal inoculation with
wild-type H5N1 at a dose of 1 3 106
TCID, the majority of the animals infected
with the transmissible virus survivedc.(Herfst et al., 2012). This clearly demon-
strates that the gain of function (GOF)
with regard to transmissibility was
accompanied by a loss of functionwith re-
gard to virulence. Thus, assessment of
how adaptations in ferrets affect viral
fitness, virulence, and transmission (both
in birds and other mammalian species) is
sorely needed to gain a truly holistic
perspective of the likelihood that these
viruses might cause a pandemic and
what characteristics such a pandemic
might exhibit. Indeed, studies in mice
(Zaraket et al., 2013) have clearly demon-
strated that the H5N1 adaptations that
increase fitness in mammals (HA-K582I)
have severe consequences on viral
fitness in waterfowl, and studies in guinea
pigs (a favored model for the study of
IAV transmission) have also revealed
striking differences in the phenotypes
associated with H5N1 infections when
compared to mice (Gao et al., 2009).
This brings us to the issue of regulatory
constraints. Understanding how factors
such as virulence, transmissibility, and
viral fitness interconnect will require
GOF experiments, the use of which has
recently been the cause of extensive con-
troversy under the new ‘‘dual-use
research of concern (DURC)’’ guidelines
(Wolinetz, 2012). GOF experiments are
(and have always been) a fundamental
pillar of scientific inquiry and are essential
to the rigorous execution of the scientific
method. Indeed, the sensationalization
and reactionary blow-back sparked by
the original H5N1 transmission studies
stem largely from scientific ignorance
with regard to how transmission, viru-
lence, and fitness interrelate. Ironically,
the only way to address this uncertainty
is to move forward with GOF studies that
will serve to contextualize how adap-
tations that mediate mammalian trans-
missibility affect other properties of the
virus (such as the dramatic reduction
in virulence observed by the Fouchier
group, for example). These studies
would serve to demystify the risks and
consequences of viral adaptations that
lead to mammalian transmissibility and
should therefore not be restricted.
Certainly, any future hopes for developing
a predictive model for pandemic risk
assessment will rely on understanding
the sumof these properties. It is important
to consider that, in the context GOF
Figure 2. Predictive Factors of Influenza Virus Vaccine Efficacy
Systems biology has facilitated the identification of pre- and postvaccination
correlates of efficacy (examples of positive correlates shown in green; negative
correlates, red). Elucidation of the mechanistic properties of thesemarkers will
allow for personalized approaches that maximize vaccine effectiveness and
will guide the development of next-generation vaccines.experiments related to H5N1
transmission, studies are
already being performed in
stringently regulated bio-
safety level 3 (BSL3) facilities
by highly skilled individuals.
This is a responsible, pre-
cautionary approach that
ensures the safety of both
the scientists performing
the studies, and the general
public.
Vexing Vaccines
The uncertain principles that
determine the pandemic risk
of IAV strains are mirrored by
similar uncertainties regard-
ing the predictability of vac-
cine responses designed to
prevent IAV infections. A
mechanistic understanding
of the genetic and environ-
mental factors that account
for the heterogeneous nature
of individual responses to the
same vaccine has long eluded
researchers, which in turn has
caused vaccine efficacy tosuffer. Though this problem is not unique
to IAV vaccines, it is additionally compli-
cated by the distinctive qualities of re-
sponses elicited by each vaccine formula-
tion (for example: split, inactivated versus
live-attenuated). Therefore, the identifica-
tion of predictive markers of vaccine effi-
cacy is a pressing need. This type of infor-
mation would not only aide in enhancing
the efficacy of current vaccines through
more personalized approaches but would
also provide a rational basis for the re-
sponses required during development of
next-generation vaccines.
Targeted, conventional approaches
have had limited success in capturing
truly predictive markers that determine
the outcome of vaccination. However,
recent advances in systems biology
offer the opportunity to undertake much
more powerful multifactorial analyses.
These efforts are beginning to yield
tremendous amounts of data regarding
the complex orchestration of factors that
govern the host response to vaccines,
some of which may have predictive
value with respect to vaccine efficacy.
The seminal study that substantiated the
utility of the systems biology approachto evaluate vaccine responses was pub-
lished in 2009 and explored the response
of humans to the highly effective yellow
fever virus YF-17D vaccine (Querec et al.,
2009). In this issue of Cell, Tsang and
colleagues (Tsang et al., 2014) describe,
for the first time, a set of baseline pre-
vaccination parameters that were found
to be predictive of postvaccination
antibody responses (Figure 2). The chal-
lenge moving forward will be to distill
the vast quantities of information obtained
through these studies in order to assign
biological significance to the observed
trends. Indeed, the fusion of systems-
level approaches with classical reduc-
tionist methods holds the promise
of revolutionizing the rational design of
vaccines.
One of the earliest systems biology
studies of influenza virus vaccine re-
sponses focused on transcriptional
analyses of peripheral blood mono-
nuclear cells (PBMCs) derived from
adult males who received the trivalent
inactivated influenza virus vaccine (TIV)
(Bucasas et al., 2011). Genes upregulated
at early time points postvaccination
were largely involved in interferon (IFN)Cell 157, April 10signaling and antigen pro-
cessing/presentation,
whereas genes upregulated
later in the response were
more likely to be asso-
ciated with cellular prolifera-
tion and protein biosynthesis.
Further refinement showed
that STAT1 upregulation
was most pronounced 24 hr
after vaccination in the high
responder group, whereas
E2F2 was downregulated
postvaccination, most promi-
nently on day 3 in the high
responder group. Remark-
ably, the postvaccination
expression profile of these
two genes alone (STAT1 and
E2F2) was sufficient to differ-
entiate high and low re-
sponders (Bucasas et al.,
2011) (Figure 2). These results
demonstrated the potential
power of systems biology ap-
proaches but also highlighted
the need for even greater
levels of resolution. For which
cell types within the PBMCpopulation do these markers primarily
apply? What mechanisms are respon-
sible for the observed outcomes? Are
these responses specific to TIV, or do
they apply more generally to other routes
of vaccination?
Elegant work by the Pulendran lab
addressed many of these issues by
analyzing the immune response to both
TIV and live-attenuated influenza virus
vaccine (LAIV) in healthy adults over
three consecutive seasons (Nakaya et al.,
2011). Consistent with previous studies
(Sasaki et al., 2007), the authors found
that vaccination with TIV elicited the
expansion of IgG-secreting plasmablasts
more efficiently than administration
of LAIV. The PBMC transcriptional sig-
natures associated with each vaccine
were also unique. The authors observed
marked transcriptional changes in genes
related to innate immunity, a trend con-
sistently observed upon transcriptional
analyses of influenza virus vaccinees.
More recent work has demonstrated
that neutrophils and monocytes are
primarily responsible for contributing to
this early IFN-related gene signature
(Obermoser et al., 2013). Upregulation, 2014 ª2014 Elsevier Inc. 297
of genes involved in the type I IFN
pathway were especially pronounced for
individuals who received LAIV, likely a
reflection of its replicative capacity. Inter-
estingly, whereas transcriptional changes
associated with B cells correlated posi-
tively with antibody titers, T-cell-asso-
ciated signatures exhibited a negative
correlation with the antibody response.
Using discriminant analysis via mixed
integer profiling (DAMIP), the authors
were able to identify and validate a mini-
mal gene signature capable of accurately
predicting the antibody responses to TIV.
Critically, to confirm the utility of their
analyses, the authors selected one of
the markers identified in the DAMIP
analysis (calcium/calmodulin-dependent
protein kinase IV [CamkIV]) for functional
validation. CamKIV expression at day 3
post-TIV vaccination negatively corre-
lated with the magnitude of the anti-
body response (Figure 2). Vaccination
of CamKIV/mice with TIV recapitulated
this effect, inducing higher antibody titers
than in control mice (Nakaya et al., 2011).
The biological signatures identified
in these and other studies have sig-
nificantly advanced our understanding
of the specific responses elicited by
various vaccines. They have also facili-
tated the identification of postvaccina-
tion markers, such as STAT1, E2F2
(Bucasas et al., 2011), CamkIV (Nakaya
et al., 2011), and CD4+ T cell levels
(Nayak et al., 2013; Spensieri et al.,
2013), which can accurately predict
the magnitude of the antibody response
elicited by influenza virus vaccination
(Figure 2). However, the ability to predict
the outcome of vaccination based on
baseline immunological markers has
remained elusive. Tsang and colleagues
provide a first glimpse of the potential
for systems biology to address this
problem. In agreement with the work
described above (Bucasas et al., 2011;
Nakaya et al., 2011; Obermoser et al.,
2013), postvaccination PBMC gene ex-
pression profiles were characterized by
strong enrichment of IFN-related gene
expression at day 1 postvaccination,
which then shifted to adaptive pathways
associated with antibody production
by day 7. These results correlated well
with changes in cell subset frequencies;
CD40+ and CD86+ monocytes and
IFNa+ plasmacytoid dendritic cell (DC)298 Cell 157, April 10, 2014 ª2014 Elsevier Inpopulations expanded most on day 1,
whereas adaptive cell types, includ-
ing plasmablasts, B cell subsets, and
T cells, were representative of the day 7
response.
Interestingly, high baseline antibody
titers were found to be inversely corre-
lated with the postvaccination response.
Baseline gene expression and pathway
activity were not robust predictors
of postvaccination response; however,
several pre-vaccination B and T cell
subpopulations were found to predict
endpoint antibody responses. Naive,
transitional, and memory B cell popula-
tions were all positively correlated with
antibody endpoint titers, whereas effector
memory CD4+ T cell and perforin+ CD8+
T cell populations exhibited a negative
correlation (Figure 2). Retrospective
analyses using these predictive cell
populations could then be used to assign
functional significance to the gene
expression signatures observed from
whole PBMCs. It should be noted that
the baseline state of antibody titers and
cellular composition of PBMCs among
individuals is likely to reflect age, at least
to some extent. Thus, the strength with
which these predictors apply to individ-
uals in different age categories remains
to be determined.
Looking into the Future
Experimental assessment of the adap-
tions required for IAV transmission
among mammals and the consequences
of these adaptations on other properties
of the virus (especially virulence and
fitness) promise to provide a more robust
framework for assessing the pandemic
risk of novel IAV strains (Linster et al.,
2014). However, this goal will require a
regulatory environment that dissolves
the unnecessary barriers that hinder
much-needed progress while maintaining
a reasonable level of oversight that en-
courages public trust. In the meantime,
the use of systems biology techniques
(Tsang et al., 2014) to assemble a more
comprehensive picture of the factors
that govern the immune response to
vaccination should serve as a guide for
the design of more efficacious vaccines.
Identifying predictive postvaccination
markers of efficacy will inform the
development of novel adjuvants (Kasturi
et al., 2011) that stimulate pathwaysc.required for optimal responses, while
baseline predictors can be exploited
to assess optimal vaccine routes/formula-
tions on an individual basis. Coupled with
ambitious ongoing efforts to elicit more
broadly protective responses against
influenza viruses (Krammer and Palese,
2014), the hope for an effective ‘‘univer-
sal’’ influenza virus vaccine may soon be
realized.
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